Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Regulatory Developments
Knowledge Centre
Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
Gastroparesis
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
PPI non-responsive GERD
Functional Dyspepsia
News
Press
>
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Expansion of the Phase 2b MOVE-IT Study of Naronapride in Gastroparesis and Dosing of the First United States Patient
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States
Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
Renexxion to Present at the Oppenheimer 34ᵗʰ Annual Healthcare Life Sciences Conference
Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic GERD
Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with PPI-non-responsive Symptomatic GERD
Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride
Renexxion to Present at the Oppenheimer Healthcare Private Company Showcase
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Contact
Our Leadership Team
Our leadership team is composed of biotech industry veterans with many years of experience in all areas of pharmaceutical drug development, management and financing.
Peter G. Milner
MD, FACC
Co-founder, Director, and Chief Executive Officer
More...
Pascal Druzgala
PhD
Co-founder, Director, and Chief Scientific Officer
More...
M. (Ken) Kengatharan
PhD, MBA
Co-founder, Director, and Chief Business Officer
More...
Ivan Coulter
PhD, MBA
Director
More...
Richard Hendrick
Director
More...
Catherine Pearson
Chief Executive Officer
More...
Mark Midei
Chief Medical Officer
More...
Elizabeth Ahrens
JD -
Coroporate Counsel
More...
Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Regulatory Developments
Knowledge Centre
Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
Gastroparesis
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
PPI non-responsive GERD
Functional Dyspepsia
News
Press
>
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Expansion of the Phase 2b MOVE-IT Study of Naronapride in Gastroparesis and Dosing of the First United States Patient
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States
Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
Renexxion to Present at the Oppenheimer 34ᵗʰ Annual Healthcare Life Sciences Conference
Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic GERD
Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with PPI-non-responsive Symptomatic GERD
Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride
Renexxion to Present at the Oppenheimer Healthcare Private Company Showcase
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Contact